Hao Xiao-Yuan, Song Wen-Wei, Li Miao-Ling, Guo Yi
Department of Obstetrics and Gynecology, The Second Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China.
Department of Laboratory Medicine, The Second Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China.
Front Pharmacol. 2024 Jul 30;15:1442022. doi: 10.3389/fphar.2024.1442022. eCollection 2024.
Ovarian cancer (OC) is a gynecological malignancy with a high mortality rate worldwide. The unfavorable prognosis of OC is mainly attributed to the recurrent propensity. Recently, mortality from OC has exhibited a downward trend. These favorable patterns are likely to be driven by advancements in novel therapeutic regimens. However, there is a lack of visualize analysis of the application of these new drugs on women with recurrent OC (ROC). Therefore, we aimed to provide a bibliometric analysis of the evolving paradigms in the ROC treatment.
Documents on ROC treatment were systematically collected from the MEDLINE database and Web of Science Core Collection (WOSCC). The retrieved documents were exported in the plain text file format, and files were named and saved to the paths specified by the Java application. Microsoft Excel (version 2010), Citespace (6.2.R4) and VOSviewer (1.6.19) were used for data analysis, and included the following: 1) annual publication trend; 2) contributions of countries, institutions and authors; 3) co-citation of journals and references; and 4) co-occurrence of keywords.
A total of 914 documents published in the MEDLINE and 9,980 ones in WOSCC were retrieved. There has been an upward trend in the productivity of publications on ROC treatment on by years. The United States was the leading contributor in this field, and the University of Texas System stood out as the most productive institution. Giovanni Scambia and Maurie Markman were the research leaders in the field of ROC treatment. The journal had the highest citation frequency. The reference entitled with "Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer" got highest centrality of 0.14 in the co-citation network. Keyword analysis revealed that the focus of current ROC treatment was on platinum-based anticancer drugs, paclitaxel, angiogenesis inhibitors (AIs), immune checkpoint inhibitors (ICIs) and poly (ADP-ribose) polymerase inhibitors (PARPis).
Scholars from a multitude of countries have been instrumental in the advancement of ROC treatment. The research hotspots and trend in the field of predominantly originated from leading international journals and specialized periodicals focused on gynecologic oncology. Maintenance therapy using AIs or (and) PARPis has emerged as a significant complement to platinum-based chemotherapy for patients with ROC.
卵巢癌（OC）是一种妇科恶性肿瘤，在全球范围内死亡率很高。OC预后不佳主要归因于其复发倾向。最近，OC的死亡率呈下降趋势。这些有利趋势可能是由新型治疗方案的进展所驱动。然而，对于这些新药在复发性OC（ROC）女性患者中的应用缺乏可视化分析。因此，我们旨在对ROC治疗中不断演变的模式进行文献计量分析。
从MEDLINE数据库和科学网核心合集（WOSCC）系统收集关于ROC治疗的文献。检索到的文献以纯文本文件格式导出，文件命名并保存到Java应用指定的路径。使用Microsoft Excel（2010版）、Citespace（6.2.R4）和VOSviewer（1.6.19）进行数据分析，包括以下内容：1）年度发表趋势；2）国家、机构和作者的贡献；3）期刊和参考文献的共被引情况；4）关键词的共现情况。
在MEDLINE中检索到914篇文献，在WOSCC中检索到9980篇文献。多年来，关于ROC治疗的出版物数量呈上升趋势。美国是该领域的主要贡献者，德克萨斯大学系统是最具生产力的机构。乔瓦尼·斯坎比亚和莫里·马克曼是ROC治疗领域的研究领军人物。该期刊的被引频次最高。参考文献“尼拉帕利维持治疗铂敏感复发性卵巢癌”在共被引网络中的中心性最高，为0.14。关键词分析表明，当前ROC治疗重点在于铂类抗癌药物、紫杉醇、血管生成抑制剂（AIs）、免疫检查点抑制剂（ICIs）和聚（ADP - 核糖）聚合酶抑制剂（PARPis）。
众多国家的学者推动了ROC治疗的进展。该领域的研究热点和趋势主要源于国际领先期刊以及专注于妇科肿瘤学的专业期刊。使用AIs或（和）PARPis的维持治疗已成为ROC患者铂类化疗的重要补充。
